<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03380624</url>
  </required_header>
  <id_info>
    <org_study_id>2016H0354</org_study_id>
    <nct_id>NCT03380624</nct_id>
  </id_info>
  <brief_title>Tear Lipid Layer Thickness With Emollient Eye Drops</brief_title>
  <official_title>Tear Lipid Layer Thickness With Emollient Eye Drops</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ohio State University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Allergan</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Ohio State University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Crossover comparison of lipid layer thickness with two artificial tear formulations&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study will objectively evaluate two US Monograph lubricant eyedrop formulations&#xD;
      (Allergan, plc). Refresh Optive ADVANCED will be compared to an investigational formula with&#xD;
      additional compendial ingredients (Refresh Optive MEGA 3) in subjects with dry eye symptoms&#xD;
      and lipid layer thickness &lt; 75 nm at baseline in a randomized, cross-over (masked subject)&#xD;
      design. We seek to objectively evaluate the increase in lipid layer thickness from baseline&#xD;
      at 15 minutes and 1 hour after each eye drop has been instilled. The Stroboscopic Video Color&#xD;
      Microscope of King-Smith is used for non-invasive lipid layer thickness measurement.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">March 1, 2017</start_date>
  <completion_date type="Actual">June 30, 2018</completion_date>
  <primary_completion_date type="Actual">June 30, 2018</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <intervention_model_description>Double masked, randomized</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Outcomes Assessor)</masking>
    <masking_description>Investigator instills eye drop masked to participant. While this is a single arm study in that all participants receive both eye drops, the order in which they are used is randomized and masked.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Change in Tear Lipid Layer Thickness</measure>
    <time_frame>15 minutes</time_frame>
    <description>Change in tear lipid layer thickness</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">21</enrollment>
  <condition>Dry Eye Syndromes</condition>
  <arm_group>
    <arm_group_label>Refresh Optive, then Refresh Optive MEGA-3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants first utilized one drop of Refresh Optive in each eye before taking lipid layer thickness measurements occurring at 15 minutes and 1 hour after instillation. After a washout period, they returned to repeat the testing using one drop of Refresh Optive MEGA-3 before taking lipid layer thickness measurements.&#xD;
.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Refresh Optive MEGA-3, then Refresh Optive</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants first utilized one drop of Refresh Optive MEGA-3 in each eye before taking lipid layer thickness measurements occurring at 15 minutes and 1 hour after instillation. After a washout period, they returned to repeat the testing using one drop of Refresh Optive before taking lipid layer thickness measurements.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Refresh Optive</intervention_name>
    <description>Lubricate and hydrating relief of eye dryness investigational lubricant eye drop is based on carboxymethylcellulose</description>
    <arm_group_label>Refresh Optive MEGA-3, then Refresh Optive</arm_group_label>
    <arm_group_label>Refresh Optive, then Refresh Optive MEGA-3</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Refresh Optive MEGA-3</intervention_name>
    <description>Lubricate and hydrating relief of eye dryness investigational lubricant eye drop is based on carboxymethylcellulose and with flaxseed oil and trehalose</description>
    <arm_group_label>Refresh Optive MEGA-3, then Refresh Optive</arm_group_label>
    <arm_group_label>Refresh Optive, then Refresh Optive MEGA-3</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age - at least 30 years&#xD;
&#xD;
               -  Good general health (defined by medication use that has not changed within the&#xD;
                  last month and the absence of medical conditions or treatments that are deemed&#xD;
                  confounding to the data as determined by the PI)&#xD;
&#xD;
               -  Ability to give informed consent&#xD;
&#xD;
               -  Willing to spend time for the study; approximately one hour for a screening visit&#xD;
                  and additional 4 hours for the study assessments. Study assessment will be&#xD;
                  conducted over 2 visit days, approximately 1 1/2 hours per day.&#xD;
&#xD;
               -  Either gender&#xD;
&#xD;
               -  Any racial or ethnic origin&#xD;
&#xD;
               -  Stroboscopic Video Color Microscope tear lipid thickness â‰¤ 75 nm&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Use of any ocular prescription medication (such as but not limited to, glaucoma&#xD;
             medications, anti-inflammatory eye drops and Restasis) used within 14 days of the&#xD;
             screening visit or started prior to the measurement visit(s).&#xD;
&#xD;
               -  Currently having punctal plugs inserted in lacrimal puncta&#xD;
&#xD;
               -  Current eye disease, infection or inflammation that affects the surface of the&#xD;
                  eye such as, but not limited to moderate or greater blepharitis and ocular&#xD;
                  allergy. Clinically significant (active treatment) of blepharitis, Sjogren's&#xD;
                  disease or other systemic disease that could influence Meibomian Gland&#xD;
                  Dysfunction, corneal, conjunctival, or eyelid abnormalities that could influence&#xD;
                  lipid layer thickness, conjunctivitis of any cause, ocular infection or systemic&#xD;
                  medication such as diuretics or drugs that could influence tear secretion, or&#xD;
                  sensitivity to any of the ingredient in the eye drop being tested,&#xD;
&#xD;
               -  Past eye surgery, such as, but not limited to, refractive surgery. Subjects who&#xD;
                  have had cataract removal surgery more than one year ago, but less than 10 years&#xD;
                  ago may be considered as potential subjects.&#xD;
&#xD;
               -  Female subjects may not be pregnant or lactating. (Subject will be asked to self&#xD;
                  report these conditions.)&#xD;
&#xD;
               -  Infectious diseases (for example, hepatitis, tuberculosis) or an&#xD;
                  immuno-suppressive disease (for example, HIV). (Subjects will be asked to&#xD;
                  self-report these conditions.)&#xD;
&#xD;
               -  Inability to complete the screening and examination&#xD;
&#xD;
               -  Inability to provide analyzable data. For example, subjects who cannot keep their&#xD;
                  eye open during the entire measurement interval (due to early blinking) or&#xD;
                  provide a readable eye image (due to eyelid laxity) or cannot sit still for 1&#xD;
                  minute.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>30 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jennifer Fogt, OD MS</last_name>
    <role>Principal Investigator</role>
    <affiliation>Ohio State University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>The Ohio State University</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43210</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2021</verification_date>
  <study_first_submitted>April 5, 2017</study_first_submitted>
  <study_first_submitted_qc>December 20, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">December 21, 2017</study_first_posted>
  <results_first_submitted>October 14, 2020</results_first_submitted>
  <results_first_submitted_qc>January 14, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">February 3, 2021</results_first_posted>
  <last_update_submitted>January 14, 2021</last_update_submitted>
  <last_update_submitted_qc>January 14, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">February 3, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Ohio State University</investigator_affiliation>
    <investigator_full_name>Jennifer Fogt</investigator_full_name>
    <investigator_title>Associate Clinical Professor - Practice</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dry Eye Syndromes</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>November 27, 2017</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/24/NCT03380624/Prot_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>2 participants were found to be ineligible after completing the baseline visit.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Refresh Optive Then Refresh Optive MEGA 3</title>
          <description>The subjects are randomly assigned to one drop of Refresh Optive or Refresh Optive MEGA followed by measurement of lipid layer thickness at 15 minutes and 1 hour After which there is a washout period before Visit 2 - in which the measurements were repeated with the other eye drop.</description>
        </group>
        <group group_id="P2">
          <title>Refresh Optive MEGA 3 Then Refresh Optive</title>
          <description>The subjects are randomly assigned to one drop of Refresh Optive or Refresh Optive MEGA followed by measurement of lipid layer thickness at 15 minutes and 1 hour After which there is a washout period before Visit 2 - in which the measurements were repeated with the other eye drop.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
                <participants group_id="P2" count="9"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
                <participants group_id="P2" count="9"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>21 subjects were enrolled. 19 completed both arms. At baseline, tear lipid layer thickness was assessed. Anyone with a tear lipid layer thickness greater than 75 nm were ineligible.</population>
      <group_list>
        <group group_id="B1">
          <title>Refresh Optive and Refresh Optive MEGA</title>
          <description>The subjects are randomly assigned to Refresh Optive or Refresh Optive MEGA (Omega 3) with measurements of lipid layer thickness following at 15 minutes and 1 hour.&#xD;
After which there is a washout period before proceeding to the second eye drop at visit 2.&#xD;
Refresh Optive: Lubricate and hydrating relief of eye dryness investigational lubricant eye drop is based on carboxymethylcellulose&#xD;
Refresh Optimum OMEGA 3: Lubricate and hydrating relief of eye dryness investigational lubricant eye drop is based on carboxymethylcellulose and with flaxseed oil and trehalose&#xD;
*All subjects completed both arms in this crossover study</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="19"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age, Customized</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Age 30 to 65</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="19"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="19"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race and Ethnicity Not Collected</title>
          <population>Race and Ethnicity were not collected from any participant.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Lipid layer thickness</title>
          <units>nm</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="19"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="40.9" spread="10.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change in Tear Lipid Layer Thickness</title>
        <description>Change in tear lipid layer thickness</description>
        <time_frame>15 minutes</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Refresh Optive</title>
            <description>Participants were first randomized to have 1 drop of Refresh Optive instilled in each eye with measurements of lipid layer thickness following at 15 minutes and 1 hour.&#xD;
After which there is a washout period before proceeding to a second visit in which Refresh Optive MEGA-3 was utilized and the measurements were repeated.&#xD;
Refresh Optive: Lubricate and hydrating relief of eye dryness investigational lubricant eye drop is based on carboxymethylcellulose&#xD;
Refresh Optimum OMEGA 3: Lubricate and hydrating relief of eye dryness investigational lubricant eye drop is based on carboxymethylcellulose and with flaxseed oil and trehalose&#xD;
*All subjects completed both arms in this crossover study</description>
          </group>
          <group group_id="O2">
            <title>Refresh Optive MEGA-3</title>
            <description>Participants were first randomized to have 1 drop of Refresh Optive MEGA-3 instilled in each eye with measurements of lipid layer thickness following at 15 minutes and 1 hour.&#xD;
After which there is a washout period before proceeding to a second visit in which Refresh Optive was utilized and the measurements were repeated.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Tear Lipid Layer Thickness</title>
          <description>Change in tear lipid layer thickness</description>
          <units>nm</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="19"/>
                <count group_id="O2" value="19"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.8" spread="14.9"/>
                    <measurement group_id="O2" value="8.8" spread="11.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>2 weeks</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Refresh Optive</title>
          <description>The subjects are randomly assigned to Refresh Optive or Refresh Optive MEGA (Omega 3) with measurements of lipid layer thickness following at 15 minutes and 1 hour.&#xD;
After which there is a washout period before proceeding to the second eye drop at visit 2.&#xD;
Refresh Optive: Lubricate and hydrating relief of eye dryness investigational lubricant eye drop is based on carboxymethylcellulose&#xD;
Refresh Optimum OMEGA 3: Lubricate and hydrating relief of eye dryness investigational lubricant eye drop is based on carboxymethylcellulose and with flaxseed oil and trehalose&#xD;
*All subjects completed both arms in this crossover study</description>
        </group>
        <group group_id="E2">
          <title>Refresh Optive MEGA</title>
          <description>The subjects are randomly assigned to Refresh Optive or Refresh Optive MEGA (Omega 3) with measurements of lipid layer thickness following at 15 minutes and 1 hour.&#xD;
After which there is a washout period before proceeding to the second eye drop at visit 2.&#xD;
Refresh Optive: Lubricate and hydrating relief of eye dryness investigational lubricant eye drop is based on carboxymethylcellulose&#xD;
Refresh Optimum OMEGA 3: Lubricate and hydrating relief of eye dryness investigational lubricant eye drop is based on carboxymethylcellulose and with flaxseed oil and trehalose&#xD;
*All subjects completed both arms in this crossover study</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="19"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="19"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Jennifer Fogt</name_or_title>
      <organization>The Ohio State University College of Optometry</organization>
      <phone>614-292-2020</phone>
      <email>fogt.78@osu.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

